Recent findings provide mechanistic clarity, positioning Selenoprotein O (SelO) as a negative regulator of HMGB1-driven inflammation and ROS-dependent neutrophil extracellular trap (NET) formation.
Transcriptomic analyses reveal a consistent downregulation of SelO in injured liver tissue, supporting its involvement in disease susceptibility. Functional studies further demonstrate that SelO deficiency amplifies inflammatory cascades following endotoxin exposure.
Specifically, SelO ablation enhances HMGB1 expression, promotes chemokine release, and intensifies pyroptotic signaling, collectively driving immune cell recruitment.
The HMGB1/ROS axis emerges as a central amplifier of hepatic injury under SelO-deficient conditions. NET overproduction not only reflects heightened inflammation but actively contributes to tissue damage, reinforcing a pathogenic feedback loop between oxidative stress and HMGB1 signaling.
These insights identify SelO as a critical upstream modulator of HMGB1 activity and NET-mediated inflammation, suggesting that restoration of redox balance or targeting HMGB1 may represent viable strategies for controlling acute liver injury.
Targeted strategies aimed at restoring redox balance or selectively inhibiting HMGB1 activity may offer new avenues for controlling acute liver inflammation and related systemic complications.
At HMGBiotech Srl, we provide comprehensive information to facilitate informed decision-making for researches using HMGB1 protein.
Read the full article about the study.
